Flutamide Tablets

This product is a non-steroidal androgen antagonist that competes with androgens for androgen receptors in tumor sites, blocks cell uptake of androgens, and inhibits the binding of androgens to target organs. After binding to androgen receptors, this product forms a receptor complex, enters the cell nucleus, and binds to nuclear proteins, thereby inhibiting tumor cell growth.

Main ingredients: 2-dimethyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide Molecular formula: C11H11F3N2O3 Molecular weight: 276.22

This product is light yellow tablet.

It is suitable for prostate cancer and is effective for both first-time and retreatment patients.

250 mg each time, orally, 3 times a day.

Male breasts become feminized, breast tenderness, sometimes accompanied by galactorrhea, which can disappear if the dose is reduced or the drug is stopped. A few patients may experience diarrhea, nausea, vomiting, increased appetite, insomnia and fatigue. Rarely, there may be decreased libido, transient liver function abnormalities and decreased sperm count. This product has less potential cardiovascular effects than diethylstilbestrol.

It is contraindicated for those who are allergic to this product.

Note for children: This experiment has not been conducted and there is no reliable reference. Note for pregnancy and lactation: This experiment has not been conducted and there is no reliable reference. Note for the elderly: This experiment has not been conducted and there is no reliable reference.

Not yet clear.

Keep away from light and store in sealed container.

0.25 g

24 months.

Jiangsu Tasly DIYI Pharmaceutical Co., Ltd.

• Founded in:

  1999-03-24

• Address:

  No. 168, Chaoyang West Road, Qingpu Industrial Park, Huai'an City

• Tax NO.:

  91320800139432975C

• Registered Funds:

  66.86 million yuan

• Website:

  Log in to view

• Email:

  Log in to view